Alto Ingredients, Inc. (ALTO): Nasdaq/NYSE listing notice — Alto Ingredients receives Nasdaq bid-price deficiency notice; 180 days to cure

Alto Ingredients, Inc.

Common stock bid price below $1.00 for 30 consecutive business days as of May 19, 2025.
Company has 180 calendar days, until November 15, 2025, to regain compliance.
Compliance requires closing at $1.00+ for at least 10 consecutive business days.
If not cured by Nov 15, may qualify for additional 180-day period subject to other listing standards.
Potential delisting if unable to cure; company may appeal to Nasdaq Hearings Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Alto Ingredients, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 19, 2025, Alto Ingredients, Inc. (the “Company”) received a letter from the listing qualifications staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, ending November 15, 2025, to regain compliance. The letter states that the Nasdaq staff will provide written notification that

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Alto Ingredients, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-047350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.